References
- [AMA] American Medical Association. 2016. Report 1 of the council on science and public health (I-16) Urine Drug Testing. Chicago (IL): American Medical Association.
- [AMDG] Washington State Agency Medical Directors’ Group. 2015. Interagency guideline on prescribing opioids for pain. Olympia (WA): Washington State Agency Medical Directors’ Group. [accessed 2018 May 23]. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf.
- [APA] American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington (DC): American Psychiatric Publishing.
- [ASAM] American Society of Addiction Medicine. 2015. National practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase (MD): American Society of Addiction Medicine.
- Arnaout B, Petrakis IL. 2010. Sedative-hypnotics and anxiolytics. New York (NY): Springer; p. 511–523.
- Arria AM, DuPont RL. 2010. Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis. 29:417–426.
- Balhara YP, Jain R. 2014. Cannabis use among opioid-dependent individuals on opioid substitution therapy. J Pharmacol Pharmacother. 5:203–205.
- Barrett AM, Walshe K, Kavanagh PV, McNamara SM, Moran C, Burdett J, Shattock AG. 2006. A comparison of five commercial immunoassays for the detection of flunitrazepam and other benzodiazepines in urine. Addict Biol. 4:81–87.
- Barthwell AG. 2016. Clinical and public health considerations in urine drug testing to identify and treat substance use. J Subst Use Misuse. 51:700–710.
- Barthwell AG, Baxter LE, Beaubler A, Bertholf RL, Brown L, Clark KJ, Cone EJ, Constantino A, Croughan J, DePriest AZ. 2013. Drug testing: a white paper of the American Society of Addiction Medicine (ASAM). Chevy Chase (MD): American Society of Addiction Medicine.
- Barthwell AG, Baxter L, Krause M, Rustin T, Kottenstette C, Fremd T, Fudin J, Dole E, Brown A. 2015. The statement of consensus on the proper utilization of urine testing in identifying and treating substance use disorders.
- Berman SM, Kuczenski R, McCracken JT, London ED. 2009. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 14:123–142.
- Berman S, O’Neill J, Fears S, Bartzokis G, London ED. 2008. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci. 1141:195–220.
- Bertol E, Vaiano F, Furlanetto S, Mari F. 2013. Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT(®) immunoassay. J Pharm Biomed Anal. 84:168–172.
- Bey T, Patel A. 2007. Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. Cal J Emerg Med. 8:9–14.
- Blum K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, Schoenthaler SJ, Oscar-Berman M, Gold MS. 2014. Systematic evaluation of “compliance” to prescribed treatment medications and “abstinence” from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One. 9:e104275.
- Borgelt L, Franson K, Nussbaum A, Wang G. 2013. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 33:195–209.
- Bradley D. 2017. Date rape drug metabolite: NMR reveals evidence next day. Hoboken (NJ): John Wiley & Sons. [accessed 2018 May 23]. http://www.spectroscopynow.com/details/ezine/15dd0614a90/Date-rape-drug-metabolite-NMR-reveals-evidence-next-day.html?tzcheck=1&&tzcheck=1& tzcheck=1.
- Brandt J, Leong C. 2017. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 17:493–507.
- Budney AJ, Higgins ST, Wong CJ. 1996. Marijuana use and treatment outcome in cocaine-dependent patients. Exp Clin Psychopharmacol. 4:396–403.
- Busardò FP, Jones AW. 2015. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 13:47–70.
- Carroll M, Carmona G, Rodefer J. 1994. Phencyclidine (PCP) self-administration and withdrawal in rhesus monkeys: effects of buprenorphine and dizocilpine (MK-801) pretreatment. Pharmacol Biochem Behav. 48:723–732.
- Carroll M, Carmona G, May S, Buzalsky S, Larson C. 1992. Buprenorphine’s effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in resus monkeys. J Pharmacol Exp Ther. 261:26–37.
- [CBHSQ] Center for Behavioral Health Statistics and Quality. 2012. The TEDS report: admissions reporting benzodiazepine and narcotic pain reliever abuse at treatment entry. Rockville (MD): Substance Abuse and Mental Health Services Administration.
- [CBHSQ] Center for Behavioral Health Statistics and Quality. 2016. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). http://www.samhsa.gov/data/.
- [CBHSQ] Center for Behavioral Health Statistics and Quality. 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Rockville (MD): Center for Behavioral Health Statistics and Quality. http://www.samhsa.gov/data/.
- [CESAR] Center for Substance Abuse Research. 2013. Flunitrazepam (Rohypnol). College Park (MD): Center for Substance Abuse Research. [accessed 2018 December 28]. http://www.cesar.umd.edu/cesar/drugs/rohypnol.asp#30.
- CESAR. 2017. Amphetamines. College Park (MD): Center for Substance Abuse Research. [accessed 2018 May 24]. http://www.cesar.umd.edu/cesar/drugs/amphetamines.asp.
- Chen KW, Berger CC, Forde DP, D’Adamo C, Weintraub E, Gandhi D. 2011. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry. 11:90.
- Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. 2003. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–1998. Addiction. 98:739–747.
- Craven C, Fileger M, Woster P. 2014. Demystifying benzodiazepine urine drug screen results. Pract Pain Manag. [accessed 2018 May 23]; [6 p.]. https://www.practicalpainmanagement.com/resources/diagnostic-tests/demystifying-benzodiazepine-urine-drug-screen-results.
- [CSAM] California Society of Addiction Medicine. 2018. The adverse effects of marijuana (for healthcare professionals). San Francisco (CA): California Society of Addiction Medicine. [accessed 2018 May 23]. http://www.csam-asam.org/adverse-effects-marijuana-healthcare-professionals.
- [CSAT] Center for Substance Abuse Treatment. 2004. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 40. 2 Pharmacology. https://www.ncbi.nlm.nih.gov/books/NBK64236/
- [CSAT] Center for Substance Abuse Treatment. 1999. Treatment for stimulant use disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 33. 2 How stimulants affect the brain and behavior.https://www.ncbi.nlm.nih.gov/books/NBK64333/.
- [CSAT] Center for Substance Abuse Treatment. 2004. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 40. 2 Pharmacology. https://www.ncbi.nlm.nih.gov/books/NBK64236/
- CSAT. 2006 Clinical issues in intensive outpatient treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 47. https://www.ncbi.nlm.nih.gov/books/NBK64093/
- CSAT. 2008. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 43. https://store.samhsa.gov/shin/content/SMA09-4341/SMA09-4341.pdf.
- Curran V, Monaghan L. 2001. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction. 96:749–760.
- Darragh A, Snyder ML, Ptolemy AS, Melanson S. 2014. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain. Pain Physician. 17:359–366.
- Davis K. 2017. What are the uses of ketamine? Brighton (UK): Medical News Today. [accessed 2018 May 23] Research:[about 10 screens.] https://www.medicalnewstoday.com/articles/302663.php.
- [DEA] Drug Enforcement Administration. 2013. Benzodiazepines. Springfield (VA): Drug Enforcement Administration. [accessed 2018 May 23]. https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf.
- DEA. 2017. Drugs of abuse: a DEA resource Guide. Springfield (VA): Drug Enforcement Administration. [accessed 2018 December 28].
- DEA. 2018. Controlled substance schedules. Springfield (VA): Drug Enforcement Administration. [accessed 2018 December 20]. https://www.deadiversion.usdoj.gov/schedules/
- Degenhardt L, Darke S, Dillon P. 2002. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 67:89–94.
- DePriest AZ, Black DL, Robert TA. 2015. Immunoassay in healthcare testing applications. J Opioid Manag. 11:13–25.
- DePriest A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ. 2010. Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use. J Anal Toxicol. 34:444–449.
- Dillon P, Copeland J, Jansen K. 2003. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 69:23–28.
- DuPont RL, Skipper GE. 2012. Six lessons from state physician health programs to promote long-term recovery. J Psychoactive Drugs. 44:72–78.
- DuPont R, Shea C, Barthwell A, Baxter L, Beaubier A, Bertholf R, Brown L, Clark K, Cone E, Costantino A. 2013. Drug testing: a white paper of the American society of addiction medicine (ASAM). Chevy Chase (MD): American Society of Addiction Medicine (ASAM).
- Ellefsen K, Anizan S, Castaneto M, Desrosiers N, Martin T, Klette K, Huestis M. 2014. Validation of the only commercially available immunoassay for synthetic cathinones in urine: randox drugs of abuse v biochip array technology. Drug Test Anal. 6:728–738.
- Elyassi AR, Long RP, Bejnarowicz RP, Schoneboom BA. 2011. Possible gabapentin and ketamine interaction causing prolonged central nervous system depression during post-operative recovery following cervical laminoplasty: a case report. J Med Case Reports. 5:167.
- Erlach SP. 2017. Sedative, hypnotic, anxiolytic use disorders. Dayton (OH): Medscape (US). [accessed 2018 May 23]. http://emedicine.medscape.com/article/290585-overview#a4.
- Fareed A, Scheinberg K, Vayalapalli S, Stout S, Gale R, Chandora A, Drexler K. 2013. Factors affecting norbuprenorphine level in monitoring clinical outcome for buprenorphine-maintained patients. Addict Disord Their Treat. 12:167–174.
- Farooq MU, Bhatt A, Patel M. 2009. Neurotoxic and cardiotoxic effects of cocaine and ethanol. J Med Toxicol. 5:134–138.
- FDA and Marijuana. 2018. Silver Spring (MD): U.S. Food & Drug Administration. [accessed 2018 December 20]. https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421163.htm.
- [FDA] U.S. Food & Drug Administration. 2006. Cesamet™. Silver Spring (MD): U.S. Food & Drug Administration. [accessed 2018 May 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf.
- FDA. 2017. FDA drug safety communication: FDA urges caution about withholding opioid addiction medications from patients taking bezodiazapines or CNS depressants: careful medication management can reduce risks. Silver Springs (MD): Food and Drug Administration. [accessed 2018 May 23]. https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm.
- Gahlinger PM. 2004. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), rohypnol, and ketamine. Am Fam Physician. 69:2619–2627.
- Gautam L, Sharratt SD, Cole MD. 2014. Drug facilitated sexual assault: detection and stability of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry. PLoS One. 9:e89031.
- Geraci MJ, Peele J, McCoy SL, Elias B. 2010. Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen. Int J Emerg Med. 3:327–331.
- Gill J, Stajic M. 2000. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci. 45:655–658.
- Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, Brink WVD. 2017. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 14:e1002396.
- Gossop M, Manning V, Ridge G. 2006. Concurrent use of alcohol and cocaine: differences in patterns of use and problems among users of crack cocaine and cocaine powder. Alcohol Alcohol. 41:121–125.
- Grant I, Atkinson J, Gouaux B, Wilsey B. 2012. Medical marijuana: clearing away the smoke. Open Neurol J. 6:18–25.
- Grella CE, Anglin MD, Wugalter SE. 1997. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am J Drug Alcohol Abuse. 23:15–42.
- Gudin JA, Mogali S, Jones JD, Comer SD. 2013. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 125:115–130.
- Gunja N. 2013. The clinical and forensic toxicology of z-drugs. J Med Toxicol. 9:155–162.
- Hammett-Stabler C, Webster L. 2008. A clinical guide to urine drug testing: augmenting paint management & enhancing patient care. Newark (NJ): University of Medicine & Dentistry of New Jersey. [accessed 2018 May 23]. http://paindr.com/wp-content/uploads/2012/06/A-Clinical-Guide-to-URINE-DRUG-TESTING.pdf.
- Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS. 2014. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry. 71:1006–1014.
- Hansen TWR. 2017. Neonatal jaundice medication. Oslo (NO): Medscape (US). [accessed 2018 May 23]. https://emedicine.medscape.com/article/974786-medication.
- Harvard Health Publishing. 2014a. Benzodiazepines (and the alternatives). Boston (MA): Harvard Medical School (US). [accessed 2018 May 23]. https://www.health.harvard.edu/newsletter_article/Benzodiazepines_and_the_alternatives.
- Harvard Health Publishing. 2014b. Substance abuse (depressants or sedative-hypnotic drugs). Boston (MA): Harvard Medical School (US). [accessed 2018 May 23]. http://www.health.harvard.edu/diseases-and-conditions/substance-abuse-depressants-or-sedative-hypnotic-drugs.
- Hattab EM, Goldberger BA, Johannsen LM, Kindi PW, Ticino F, Chronister CW, Bertholf RL. 2000. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci. 30:85–91.
- Heikman P, Häkkinen M, Gergov M, Ojanperä I. 2014. Urine naloxone concentration at different phases of buprenorphine maintenance treatment. Drug Test Anal. 6:220–225.
- Helander A, Bottcher M, Fehr C, Dahmen N, Beck O. 2009. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 44:55–61.
- Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG. 2008. Urinary buprenorphine concentrations in patients treated with Suboxone was determined by liquid chromatography–mass spectrometry and CEDIA immunoassay. J Anal Toxicol. 2008;32:516–521.
- Jaffe A, Molnar S, Williams N, Wong E, Todd T, Caputo C, Tolentino J, Ye S. 2016. Review and recommendations for drug testing in substance use treatment contexts. J Reward Defic Syndr Addict Sci. 2:28–45.
- Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, Luongo P, Safarian T. 2017. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 11:163–173.
- Jhanjee S. 2014. Evidence based psychosocial interventions in substance use. Indian J Psychol Med. 36:112–118. https://doi.org/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031575/
- JHP Pharmaceuticals, LLC. 2012. Ketalar – ketamine hydrochloride injection. Rochester (MI): JHP Pharmaceuticals, LLC. [accessed 2018 May 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016812s039lbl.pdf.
- Johnson-Davis K, Sadler A, Genzen J. 2016. A retrospective analysis of urine drugs of abuse immunoassay true positive rates at a national reference laboratory. J Anal Toxicol. 40:97–107.
- Jones H. 2004. Practical considerations for the use of buprenorphine. Farmington (CT): National Alliance of Advocates for Buprenorphine Treatment. [accessed 2018 May 23] https://www.naabt.org/documents/Practical_Conciderations%20.pdf.
- Jones CM, McAninch JK. 2015. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 49:493–501.
- Jones JD, Mogali S, Comer SD. 2012. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 125:8–18.
- Kaabneh MAF, Salama GAS, Shakkoury AGA, Al-abdallah IMH, Alshamari A, Halaseh RAA. 2015. Phenobarbital and phototherapy combination enhances decline of total serum bilirubin and may decrease the need for blood exchange transfusion in newborns with isoimmune hemolytic disease. Clin Med Insights Pediatr. 2015:67–72.
- Kampman K, Jarvis M. 2015. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 9:358–367.
- Kaplan YC, Erol A, Karadaş B. 2012. False-positive amphetamine/ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate. Ther Drug Monit. 34:493–495.
- Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, et al. 2007. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 23:648–660.
- Kilmer B, Nicosia N, Heaton P, Midgette G. 2013. Efficacy of frequent monitoring with swift, certain, and modest sanctions for violations: insights from South Dakota’s 24/7 Sobriety Project. Am J Public Health. 103:e37–e43.
- Kirsh KL, Heit HA, Huskey A, Strickland J, Egan K, Passik SD. 2015. Trends in drug use from urine drug testing of addiction treatment clients. J Opioid Manag. 11:61–68.
- Kolar AF, Brown BS, Weddington WW, Ball JC. 1990. A treatment crisis: cocaine use by clients in methadone maintenance programs. J Subst Abuse Treat. 7:101–107.
- Kripke DF. 2000–2013. Risks of chronic hypnotic use. Madame curie bioscience database [Internet]. Austin (TX): Landes Bioscience. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6630/.
- Lamonica AK, Boeri M. 2012. An exploration of the relationship between the use of methamphetamine and prescription drugs. J Ethnogr Qual Res. 6:160.
- Landy GL, Kripalani M. 2015. False positive phencyclidine result on urine drug testing: a little known cause. BJPsych Bull. 39:50.
- Lavie E, Fatseas M, Denis C, Auriacombe M. 2009. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Ethanol Depend. 99:338–344.
- Lee HH, Lee JF, Lin SY, Lin YY, Wu CF, Wu MT, Chen BH. 2013. Simultaneous quantification of urine flunitrazepam, nimetazepam and nitrazepam by using liquid chromatography tandem mass spectrometry. Clin Chim Acta. 420:134–139.
- Lin HR, Lin HL, Lee S, Liu C, Lua A. 2010. A fast screening procedure for ketamine and metabolites in urine samples with tandem mass spectrometry. J Anal Toxicol. 34:149–154.
- Lindsay JA, Stotts AL, Green CE, Herin DV, Schmitz JM. 2009. Cocaine dependence and concurrent marijuana use: a comparison of clinical characteristics. Am J Drug Alcohol Abuse. 35:193–198.
- Ling W, Mooney L, Hillhouse M. 2011. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 30:300–305.
- Liu CH, Wang HY, Shen SH, Chiu YW. 2017. False positive ketamine urine immunoassay screen result induced by quetiapine: a case report. J Formosan Med Assoc. 116:720–722.
- Lofwall MR, Walsh SL. 2014. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 8:315–326.
- Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. 1994. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav. 48:715–721.
- Mayo Clinic. 2017. Barbiturate (oral route, parenteral route, rectal route). Rochester (MN): Mayo Foundation for Medical Education and Research. [accessed 2018 May 23]. https://www.mayoclinic.org/drugs-supplements/barbiturate-oral-route-parenteral-route-rectal-route/description/drg-20069290dical.
- McCance-Katz EF, Sullivan L, Nallani S. 2010. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 19:4–16.
- McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE. 2012. Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 36:81–87.
- Melanson SE, Snyder ML, Jarolim P, Flood JG. 2012. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. J Anal Toxicol. 36:201–206.
- Mello NK, Negus SS. 2007. Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine + heroin) self-administration by rhesus monkeys. Neuropsychopharmacology. 32:1985–1994.
- Melnikova N, Welles WL, Wilburn RE, Rice N, Wu J, Stanbury M. 2011. Hazards of illicit methamphetamine production and efforts at reduction: data from the hazardous substances emergency events surveillance system. Public Health Rep. 126:116–123.
- Miller KL, Puet BL, Roberts A, Hild C, Carter J, Black DL. 2017. Urine drug testing results and paired oral fluid comparison from patients enrolled in long-term medication-assisted treatment in Tennessee. J Subst Abus Treat. 76:36–42.
- Moeller KE, Lee KC, Kissack JC. 2008. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 83:66–76.
- Mohamed W, Hamida S, Cassel J, de Vasconcelos A, Jones B. 2011. MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav. 99:759–774.
- [AMA] American Medical Association. 2016. Report 1 of the council on science and public health (I-16): Urine drug testing. Chicago (IL): American Medical Association.
- Nair H, Clarke W, editors. 2016. Mass spectrometry for the clinical laboratory. Cambridge (MA): Academic Press.
- [NDIC] National Drug Intelligence Center. 2003a. PCP fast facts. Johnstown (PA): National Drug Intelligence Center. [accessed 2018 May 23]. https://www.justice.gov/archive/ndic/pubs4/4440/.
- NDIC. 2003b. Rohypnol fast facts. Johnstown (PA): (NDIC) National Drug Intelligence Center. [accessed 2018 May 23] https://www.justice.gov/archive/ndic/pubs6/6074/6074p.pdf.
- [NIDA] National Institute on Drug Abuse. 2016a. Monitoring the future 2016 survey results. Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/related-topics/trends-statistics/infographics/monitoring-future-2016-survey-results.
- NIDA. 2016b. What are the short-term effects of cocaine abuse. Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/publications/research-reports/cocaine/what-are-short-term-effects-cocaine-use.
- NIDA. 2016c. What is cocaine? Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/publications/drugfacts/cocaine.
- NIDA. 2017a. MDMA (ecstasy) abuse. Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23] https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/what-mdma.
- NIDA. 2017b. Opioids. Rockville (MD): National Institute on Drug Abuse (US). [accessed 2018 May 23]. https://www.drugabuse.gov/drugs-abuse/opioids.
- NIDA. 2017c. Overdose Death Rates. Bethesda (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates.
- NIDA. 2018a. Commonly abused drugs charts (Bath Salts). Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts#synthetic-cathinones-bath-salts-.
- NIDA. 2018b. Commonly abused drugs charts (GHB). Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts#ghb.
- NIDA. 2018c. Treatment approaches for drug addiction. Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction.
- NIDA. 2018d. What is marijuana? Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/publications/drugfacts/marijuana.
- NIDA. 2018e. Urine drug testing for pain management. Rockville (MD): National Institute on Drug Abuse. [accessed 2018 May 23]. https://www.drugabuse.gov/sites/default/files/files/UrineDrugTesting.pdf.
- Owen GT, Burton AW, Schade CM, Passik S. 2012. Urine drug testing: current recommendations and best practices. Pain Physician. 15:ES119–ES133.
- Palmetto GBA. 2018. Local Coverage Determination (LCD): Controlled Substance Monitoring and Drugs of Abuse Testing (L5724). Columbia (SC): Palmetto GBA..
- Partnership for Drug-Free Kids. 2018. Ketamine. New York (NY): Partnership for Drug-Free Kids. [accessed 2018 May 23]. https://drugfree.org/drug/ketamine/.
- Passik S, Heit H, Rzetelny A, Pesce A, Mikel C, Kirsh K. 2013. Trends in drug and illicit use from urine drug testing from addiction treatment clients. Proceedings of the International Conference on Opioids. ASAM White Paper, Boston (MA).
- Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latyshev S, Horn PS. 2010. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 13:283–287.
- Pesce A, West C, Egan City K, Strickland J. 2012a. Interpretation of urine drug testing in pain Patients. Pain Med. 13:868–885.
- Pesce A, West C, West R, Latyshev S, Masters-Moore D, Friel P, Hughes JM, Almazan P, Gonzales E. 2012b. Analytical considerations when monitoring pain medications by LC-MS/MS. J Anal Bioanal Tech. S5:003.
- Petry NM, Martin B, Simcic F. Jr. 2005. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. J Consult Clin Psychol. 73:354–359.
- Pilowsky DJ, Wu LT, Burchett B, Blazer DG, Woody GE, Ling W. 2011. Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil. 2:133–144.
- Prosser JM, Nelson LS. 2012. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 8:33–42.
- Reckitt Benckiser Pharmaceuticals Inc. 2011. NDA 20-733 Suboxone (buprenorphine and naloxone) sublingual tablet CIII buprenorphine (opioid partial agonist-antagonist) naloxone (opioid antagonist). Richmond (VA): Reckitt Benckiser Pharmaceuticals Inc. (US). Referencce No. 3063079. Available from: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm285895.pdf.
- Reisfield G, Wasan A, Jamison R. 2009a. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 10:1434–1441.
- Reisfield GM, Goldberger BA, Bertholf RL. 2009b. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 1:937–952.
- Reisfield GM, Salazar E, Bertholf RL. 2007. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 37:301–314.
- Riahi-Zanjani B. 2014. False positive and false negative results in urine screening tests: tampering methods and specimen integrity tests. Pharmacologyonline. 1:102–108.
- Richards JR, Laurin EG. 2018. Cocaine. StatPearls [Internet].Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430769/.
- Roux P, Carrieri P, Cohen J, Ravaux I, Spire B, Gossop M, Comer SD. 2011. Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach. Harm Reduct J. 8:31.
- Ruan X, Kaye AD. 2015. The debate on urine drug testing in pain and addiction management: coverage or non-coverage? J Pain Relief. 4:188.
- Rudd RA, Seth P, David F, Scholl L. 2016. Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. Atlanta (GA): Centers for Disease Control and Prevention (US). Report No. 65, 1445–1452. https://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm.
- Rzetelny A, Zeller B, Miller N, City KE, Kirsh KL, Passik SD. 2016. Counselors’ clinical use of definitive drug testing results in their work with substance-use clients: a qualitative study. Int J Ment Health Addict. 14:64–80.
- Saitman A, Park H, Fitzgerald R. 2014. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol. 38:387–396.
- SAMHSA Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2014. The DAWN Report: Benzodiazepines in Combination with Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes. Rockville (MD): Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality.
- [SAMHSA] Substance Abuse and Mental Health Services Administration. 2012. Pharmacologic guidelines for treating individuals with post-traumatic stress disorder and co-occurring opioid use disorders (HHS Publication No. SMA-12-4688). Rockville (MD): Substance Abuse and Mental Health Services Administration.
- SAMHSA. 2013. The DAWN report: emergency department visits involving phencyclidine (PCP). Rockville (MD); Substance Abuse and Mental Health Services Administration (SAMHSA).
- SAMHSA. 2015. Medication and counseling treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). [accessed 2018 May 23]. https://www.samhsa.gov/medication-assisted-treatment/treatment.
- SAMHSA. 2016a. Buprenorphine. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). [accessed 2018 May 23]. https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine.
- SAMHSA. 2016b. Results from the 2016 Capitalize National Survey on Drug Use and Health: detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration. [accessed 2018 May 23]. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm#tab1-22B.
- Schwarz DA, George MP, Bluth MH. 2016. Toxicology in addiction medicine. Clin Lab Med. 36:685–692.
- Skalisky J, Leickly E, Oluwoye O, McPherson S, Srebnik D, Roll J, Ries R, McDonell M. 2017. Prevalence and correlates of cannabis use in outpatients with serious mental illness receiving treatment for alcohol use disorders. Cannabis Cannabinoid Res. 2:133–138.
- Snyder M, Fantz C, Melanson S. 2017. Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain. Pain Physician. 20:SE1–SE9.
- Standridge JB, Adams SM, Zotos AP. 2010. Urine drug screening: a valuable office procedure. Am Fam Physician. 81:635–640.
- Strike C, Rufo C. 2010. Embarrassing, degrading, or beneficial: patient and staff perspectives on urine drug testing in methadone maintenance treatment. J Subst Use. 15:303–312.
- SAMHSA 2013b. The DAWN report: emergency department visits involving phencyclidine (PCP). Rockville (MD): Substance Abuse and Mental Health Services Administration.
- SAMHSA. 2013c. Emergency department visits for adverse reactions involving the insomnia medication zolpidem. Rockville (MD): Substance Abuse and Mental Health Services Administration.
- Sullivan LE, Moore BA, O’Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. 2009. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict. 19:53–58.
- Suzuki J, Zinser J, Issa M, Rodriguez C. 2017. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment. Subst Abus. 38:504–507.
- Thai D, Dyer J, Benowitz N, Haller C. 2006. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 26:524–529.
- The Council of Economic Advisers. 2017. The underestimated cost of the opioid crisis. Washington (DC): The Executive Office of the President of the United States. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf.
- The Pew Charitable Trusts. 2016. Medication-assisted treatment improves outcomes for patients with opioid use disorder. Washington (DC): The Pew Charitable Trusts (US). [accessed 2018 May 23]. http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2016/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorder.
- Trujillo KA, Smith ML, Guaderrama MM. 2011. Powerful behavioral interactions between methamphetamine and morphine. Pharmacol Biochem Behav. 99:451–458.
- [AMA] American Medical Association. 2016. Report 1 of the council on science and public health (I-16): Urine drug testing. Chicago (IL): American Medical Association.
- Visconti AJ, Santos GM, Lemos NP, Burke C, Coffin PO. 2015. Opioid overdose deaths in the city and county of San Francisco: prevalence, distribution, and disparities. J Urban Health. 92:758–772.
- Volkow N, Baler R, Compton W, Weiss S. 2014. Adverse health effects of marijuana use. N Engl J Med. 370:2219–2227.
- Volkow ND, McLellan AT. 2016. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N Engl J Med. 374:1253–1263.
- Wasserman DA, Weinstein MG, Havassy BE, Hall SM. 1998. Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend. 52:183–192.
- Weathermon R, Crabb DW. 1999. Alcohol and medication interactions. Alcohol Res Health. 23:40–54.
- Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. 2014. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 348:g1996.
- Wessinger WD, Balster RL. 1987. Interactions between phencyclidine and central nervous system depressants evaluated in mice and rats. Pharmacol Biochem Behav. 27:323–332.
- [WPSIC] Wisconsin Physicians Service Insurance Corporation. 2018. Local coverage determination (LCD): drug testing (L34645). Madison (WI): Wisconsin Physicians Service Insurance Corporation.
- Yasgur BS. 2018. Gabapentin and opioids a potentially deadly combination. [accessed 2018 May 23]. Research: [about 4 screens]. https://www.painmedicinenews.com/Clinical-Pain-Medicine/Article/03-18/Gabapentin-and-Opioids-a-Potentially-Deadly-Combination/47053?sub=C143BC655DA759D99E56383AE3C0C55ECB64ABF25DFEFEA185C6CA3F4F86B4&enl=true&lipi=urn:li:page:d_flagship3_feed;y0AoiQmuRTy3ozEhwaJ0iQ%3D%3D